RxDoctor Payments Data

Dilafruz Elnasser

Adult Health · Depew, NYNPI 1902344385

Payments from drug & device makers

$1,341in general payments, 2019–2025

Across 17 payments — averaging $78.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$375
  • Teva Pharmaceuticals USA, Inc.$270
  • AstraZeneca$239
  • Otsuka America Pharmaceutical, Inc.$146
  • Neurocrine Biosciences, Inc.$125
  • Idorsia Pharmaceuticals US Inc$125
  • plus $61 from 2 others

What the payments were for

  • Food & beverage$1,341100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,341 in reported general payments places this provider in the 70th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$48,269
Medicare patients
121
Services billed
602

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban344$146,495
JardianceEmpagliflozin108$69,288
TrulicityDulaglutide37$45,463
XifaxanRifaximin11$36,836
XareltoRivaroxaban37$30,604
MyrbetriqMirabegron55$25,779
GlatopaGlatiramer Acetate12$23,531
EntrestoSacubitril/Valsartan24$15,878
OzempicSemaglutide15$15,076
TradjentaLinagliptin24$12,178
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$11,961
JanuviaSitagliptin Phosphate22$11,309
MovantikNaloxegol Oxalate73$10,784
LinzessLinaclotide19$10,614
CreonLipase/Protease/Amylase52$9,279

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$23$45,46337 claims
AbbVieLinzess, Creon$38$19,89371 claims
AstraZenecaBrilinta, Symbicort$239$9,81628 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,828 adult health providers in New York.

Other adult health in Depew

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →